The DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Foxm1b transcription factor is essential for development of hepatocellular carcinomas and is negatively regulated by the p19ARF tumor suppressor
Open accessAbstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths worldwide. Here, we provide evidence that the Forkhead Box (Fox) m1b (Foxm1b or Foxm1) transcription factor is essential for the development of HCC. Conditionally deleted Foxm1b mouse hepatocytes fail to proliferate and are highly resistant to developing HCC in response to a Diethylnitrosamine (DEN)/Phenobarbital (PB) liver tumor-induction protocol. The mechanism of resistance to HCC development is associated with nuclear accumulation of the cell cycle inhibitor p27 Kip1 protein and reduced expression of the Cdk1-activator Cdc25B phosphatase. We showed that the Foxm1b transcription factor is a novel inhibitory target of the p19 ARF tumor suppressor. Furthermore, we demonstrated that conditional overexpression of Foxm1b protein in osteosarcoma U2OS cells greatly enhances anchorage-independent growth of cell colonies on soft agar. A p19 ARF 26–44 peptide containing nine D-Arg to enhance cellular uptake of the peptide was sufficient to significantly reduce both Foxm1b transcriptional activity and Foxm1b-induced growth of U2OS cell colonies on soft agar. These results suggest that this (D-Arg)9-p19 ARF 26–44 peptide is a potential therapeutic inhibitor of Foxm1b function during cellular transformation. Our studies demonstrate that the Foxm1b transcription factor is required for proliferative expansion during tumor progression and constitutes a potential new target for therapy of human HCC tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
CDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor
Brunet, A., Bonni, A., Zigmond, M. J., Lin, M. Z., Juo, P., Hu, L. S., Anderson, M. J., Arden, K. C., Blenis, J., & Greenberg, M. E. (1999) · Cell · doi:10.1016/s0092-8674(00)80595-4 · Cited by 5,594
Nuclear Receptors and Lipid Physiology: Opening the X-Files
Chawla, A., Repa, J. J., Evans, R. M., & Mangelsdorf, D. J. (2001) · Science · doi:10.1126/science.294.5548.1866 · Cited by 2,085
Polyak, K., Kato, J. Y., Solomon, M. J., Sherr, C. J., Massague, J., Roberts, J. M., & Koff, A. (1994) · Genes & Development · doi:10.1101/gad.8.1.9 · Cited by 1,954
The RB and p53 pathways in cancer
Sherr, C. J., & McCormick, F. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00102-2 · Cited by 1,690 · cited 6×
“Loss of p19 function is a critical event for tumor promotion, as evidenced by extinguished expression of the p19 protein in a variety of tumors through DNA methylation and silencing of the p19 promoter region (Sherr and McCormick 2002).”
BackgroundResultInfluentialWender, P. A., Mitchell, D. J., Pattabiraman, K., Pelkey, E. T., Steinman, L., & Rothbard, J. B. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.24.13003 · Cited by 1,615
Tumor Suppression at the Mouse INK4a Locus Mediated by the Alternative Reading Frame Product p19
Kamijo, T., Zindy, F., Roussel, M. F., Quelle, D. E., Downing, J. R., Ashmun, R. A., Grosveld, G., & Sherr, C. J. (1997) · Cell · doi:10.1016/s0092-8674(00)80452-3 · Cited by 1,566
Pomerantz, J., Schreiber-Agus, N., Liégeois, N. J., Silverman, A., Alland, L., Chin, L., Potes, J., Chen, K., Orlow, I., Lee, H.-W., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81400-2 · Cited by 1,521 · cited 1×
“The p19ARF (p19) protein targets the p53 negative regulator Mdm2 to the nucleolus, thus stabilizing the p53 transcription factor, which regulates genes mediating G1 cell cycle arrest and/or apoptosis (Palmero et al. 1998; Pomerantz et al. 1998; Weber et al. 1999).”
BackgroundOuelle, D. E., Zindy, F., Ashmun, R. A., & Sherr, C. J. (1995) · Cell · doi:10.1016/0092-8674(95)90214-7 · Cited by 1,485
AFX-like Forkhead transcription factors mediate cell-cycle regulation by Ras and PKB through p27kip1
Medema, R. H., Kops, G. J. P. L., Bos, J. L., & Burgering, B. M. T. (2000) · Nature · doi:10.1038/35008115 · Cited by 1,438
Cited by
Chen, Y., Wang, L., Kang, Q., Zhang, X., Yu, G., Wan, X., Wang, J., & Zhu, K. (2017) · Cellular Physiology and Biochemistry · doi:10.1159/000477308 · Cited by 10,679
Hepatocellular Carcinoma: Epidemiology and Molecular Carcinogenesis
El–Serag, H. B., & Rudolph, K. L. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.04.061 · Cited by 5,415
Maeda, S., Kamata, H., Luo, J.-L., Leffert, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,164
The emerging roles of forkhead box (Fox) proteins in cancer
Myatt, S. S., & Lam, E. W. F. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2223 · Cited by 1,070
Basal cell carcinomas: attack of the hedgehog
Epstein, E. H. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2503 · Cited by 834
Forkhead box proteins: tuning forks for transcriptional harmony.
Lam, E. W.-F., Brosens, J. J., Gomes, A. R., & Koo, C.-Y. (2013) · Nature Reviews Cancer · doi:10.1038/nrc3539 · Cited by 684
The evolution of Fox genes and their role in development and disease
Hannenhalli, S., & Kaestner, K. H. (2009) · Nature Reviews Genetics · doi:10.1038/nrg2523 · Cited by 658
Wang, I.-C., Chen, Y.-J., Hughes, D., Petrovic, V., Major, M. L., Park, H. J., Tan, Y., Ackerson, T., & Costa, R. H. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.24.10875-10894.2005 · Cited by 627
Self-citationDivorcing ARF and p53: an unsettled case
Sherr, C. J. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1954 · Cited by 595
Zhang, N., Wei, P., Gong, A., Chiu, W.-T., Lee, H.-T., Colman, H., Huang, H., Xue, J., Liu, M., Wang, Y., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.016 · Cited by 584
Anders, L., Ke, N., Hydbring, P., Choi, Y. J., Widlund, H. R., Chick, J. M., Zhai, H., Vidal, M., Gygi, S. P., Braun, P., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.10.001 · Cited by 543
Lin, R., Maeda, S., Liu, C., Karin, M., & Edgington, T. S. (2007) · Oncogene · doi:10.1038/sj.onc.1209846 · Cited by 510
Transcriptional Control of Lung Morphogenesis
Maeda, Y., Davé, V., & Whitsett, J. A. (2007) · Physiological Reviews · doi:10.1152/physrev.00028.2006 · Cited by 473
Regulation of the master regulator FOXM1 in cancer
Liao, G.-B., Li, X.-Z., Zeng, S., Liu, C., Yang, S.-M., Yang, L., Hu, C.-J., & Bai, J.-Y. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0266-6 · Cited by 417
FOXM1: From cancer initiation to progression and treatment
Koo, C.-Y., Muir, K. W., & Lam, E. W.-F. (2012) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2011.09.004 · Cited by 406
Inhibitors of cyclin-dependent kinases as cancer therapeutics.
Whittaker, S. R., Mallinger, A., Workman, P., & Clarke, P. A. (2017) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2017.02.008 · Cited by 384
New therapies for hepatocellular carcinoma
Avila, M. A., Berasain, C., Sangro, B., & Prieto, J. (2006) · Oncogene · doi:10.1038/sj.onc.1209550 · Cited by 383
FoxM1: At the crossroads of ageing and cancer
Laoukili, J., Stahl, M., & Medema, R. H. (2007) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2006.08.006 · Cited by 377
Wonsey, D. R., & Follettie, M. T. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4059 · Cited by 349
Kim, I.-M., Ackerson, T., Ramakrishna, S., Tretiakova, M., Wang, I.-C., Kalin, T. V., Major, M. L., Gusarova, G. A., Yoder, H. M., Costa, R. H., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3003 · Cited by 337
Self-citationLiu, M., Dai, B., Kang, S.-H., Ban, K., Huang, F.-J., Lang, F. F., Aldape, K. D., Xie, T.-X., Pelloski, C. E., Xie, K., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2912 · Cited by 314
FOXM1, a typical proliferation-associated transcription factor
Wierstra, I., & Alves, J. (2007) · bchm · doi:10.1515/bc.2007.159 · Cited by 313
FoxM1: A Master Regulator of Tumor Metastasis
Raychaudhuri, P., & Park, H. J. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0640 · Cited by 308
Self-citationNucleophosmin (B23) Targets ARF to Nucleoli and Inhibits Its Function
Korgaonkar, C., Hagen, J., Tompkins, V., Frazier, A. A., Allamargot, C., Quelle, F. W., & Quelle, D. E. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.4.1258-1271.2005 · Cited by 292
Lynch, T. P., Ferrer, C. M., Jackson, S. R., Shahriari, K. S., Vosseller, K., & Reginato, M. J. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.302547 · Cited by 286
Kalin, T. V., Wang, I.-C., Ackerson, T. J., Major, M. L., Detrisac, C. J., Kalinichenko, V. V., Lyubimov, A., & Costa, R. H. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3138 · Cited by 274
Self-citationThe Cell-Cycle Regulator CDK4: An Emerging Therapeutic Target in Melanoma
Sheppard, K. E., & McArthur, G. A. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-0259 · Cited by 265
Kwok, J. M.-M., Myatt, S. S., Marson, C. M., Coombes, R. C., Constantinidou, D., & Lam, E. W.-F. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0188 · Cited by 252
Blanco‐Bose, W. E., Murphy, M. J., Ehninger, A., Offner, S., Dubey, C., Huang, W., Moore, D. D., & Trumpp, A. (2008) · Hepatology · doi:10.1002/hep.22475 · Cited by 138
Chen, W.-D., Wang, Y.-D., Zhang, L., Shiah, S., Wang, M., Yang, F., Yu, D., Forman, B. M., & Huang, W. (2010) · Hepatology · doi:10.1002/hep.23390 · Cited by 115
Deregulation of the Hippo pathway in soft-tissue sarcoma promotes FOXM1 expression and tumorigenesis
Eisinger-Mathason, T. S. K., Mucaj, V., Biju, K. M., Nakazawa, M. S., Gohil, M., Cash, T. P., Yoon, S. S., Skuli, N., Park, K. M., Gerecht, S., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1420005112 · Cited by 103
Activating CAR and β-catenin induces uncontrolled liver growth and tumorigenesis
Dong, B., Lee, J.-S., Park, Y.-Y., Yang, F., Xu, G., Huang, W., Finegold, M. J., & Moore, D. D. (2015) · Nature Communications · doi:10.1038/ncomms6944 · Cited by 97
“Overexpression of FoxM1 is associated with the development and progression of many cancers including lung, prostate, pancreatic, glioblastoma and HCC 33, 34, 35 .”
Expression of Foxm1 Transcription Factor in Cardiomyocytes Is Required for Myocardial Development
Bolte, C., Zhang, Y., Wang, I.-C., Kalin, T. V., Molkentin, J. D., & Kalinichenko, V. V. (2011) · PLoS ONE · doi:10.1371/journal.pone.0022217 · Cited by 83
Self-citationMarthandan, S., Menzel, U., Priebe, S., Groth, M., Guthke, R., Platzer, M., Hemmerich, P., Kaether, C., & Diekmann, S. (2016) · Biological Research · doi:10.1186/s40659-016-0095-2 · Cited by 39
Metadata
- Authors
- Kalinichenko, V. V., Major, M. L., Wang, X., Petrovic, V., Kuechle, J., Yoder, H. M., Dennewitz, M. B., Shin, B., Datta, A., Raychaudhuri, P., & Costa, R. H.
- Venue
- Genes & Development
- Publisher
- Cold Spring Harbor Laboratory
- Published
- 2004-04-01
- Volume
- 18
- Issue
- 7
- Pages
- 830-850
- ISSN
- 0890-9369 (ISSN-L)
- 1549-5477
- OpenAlex
- W2158838322
- Cited by
- 356
- References
- 73
- Type
- posted content
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.